History of Natco Pharma Limited

_x000D_ Incorporated in 1981, Natco Pharma Limited is involved in the manufacturing and sale of pharmaceutical products. _x000D_ _x000D_ The company was started in 1981 in Kothur, Mahaboobnagar district, Telangana. In 1986, they opened a parental manufacturing unit at Nagarjunasagar. In 1993, the company inaugurated a chemical division at Mekaguda. In 1995, Natco Trust was founded, and Natco merged three of the group companies with the parent company. In the same year, they went public and got listed on the Indian stock exchanges. In 1997, they opened the Natco Research Centre (NRC). _x000D_ _x000D_ In 2003, the company entered the Oncology division and launched its flagship brand, Veenat. In 2006, Natco Pharma Limited established a finished dosage unit at Dehradun. In the next year, i.e., in 2007, they launched their first Abbreviated New Drug Application (ANDA) in the USA. They also acquired Savemart Pharmacy in the USA. In 2009, the company established Natco Organics in Chennai, and in the same year, the company turnover touched $100 million. Between 2013 and 2014, the company established in Canada and Australia. _x000D_ _x000D_ In 2016, Natco Pharma Limited sold Savemart Pharmacy in the USA. In 2017, they entered the Diabetology and Cardiology divisions. In 2018, they launched Teriflunomide, the company’s first generic version of oral tablets for multiple sclerosis in India. In 2019, they launched the crop health science division. In 2020, the company’s Vishakapatnam Formulation unit was approved by the US FDA. In the same year, Natco Pharma supplied COVID-19 treatment tablets, Chloroquine Phosphate tablets in the USA. In 2021, the company launched other drugs for Covid treatment. In 2022, Natco Pharma’s crop health science division launched agro products in India. _x000D_ _x000D_ As of March 2023, Natco Pharma Limited has a presence in more than 50 countries and 465 scientists. They have 5 Finished Dosage Forms (FDF) manufacturing units, 2 Active Pharmaceutical Ingredients (API) manufacturing units, 2 R&D centres and 2 crop health sciences units. _x000D_

Business Segments of Natco Pharma Limited 

_x000D_ The two primary business segments of the company are as follows: _x000D_

_x000D_
• Pharmaceuticals: In this segment, the company is involved in the development, manufacturing and marketing of FDF and APIs. 
_x000D_

_x000D_

_x000D_
• Agrochemicals: In this segment, the company focuses on providing eco-friendly biopesticide products for farmers, thus contributing to sustainable farming.
_x000D_

_x000D_ As of March 31, 2023, a few of the subsidiaries of Natco Pharma Limited are as follows:_x000D_

_x000D_
• Natco Pharma Inc: This wholly-owned subsidiary of the company is involved in the retail sale of prescription drugs and non-prescription medicines. 
_x000D_

_x000D_

_x000D_
• Natco Pharma Australia Pty Ltd: This wholly-owned subsidiary of the company was established for the sale and distribution of pharmaceutical products in Australia. 
_x000D_

_x000D_

_x000D_
• Natco Pharma (Canada) Inc: This wholly-owned subsidiary of the company was established for the sale and distribution of pharmaceutical products in Canada. 
_x000D_

_x000D_

Key Personalities of Natco Pharma Limited

_x000D_ V.C. Nannapaneni, Managing Director_x000D_ _x000D_ V.C. Nannapaneni is the Managing Director of Natco Pharma Limited. He has more than 40 years of experience in the pharmaceutical sector. In addition to handling general management responsibilities, he supervises the New Drug Discovery program within the company.